GenexGen develops epigenetic therapies that modulate immune pathways previously considered undruggable. Its lead program delivers mRNA‑encoded epigenetic repressors to silence MYD88, providing a targeted treatment for hemophagocytic lymphohistiocytosis. The platform is designed to address broader chronic inflammation and age‑related immune dysfunction.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer and autoimmune disease treatments often have limited efficacy due to the body's immune system suppressing the therapeutic effects. This immune suppression hinders the ability of immunotherapies and vaccinations to effectively combat these diseases.
Solution
The company is developing novel immune suppressive therapies using CRISPR technology to precisely modify epigenetic and cellular mechanisms within the immune system. By targeting these mechanisms, the therapies aim to enhance the effectiveness of immunotherapies and vaccinations, leading to improved patient outcomes in cancer and autoimmune disease management. This approach seeks to overcome the limitations of existing treatments by modulating the immune response to promote therapeutic efficacy.
Target Audience
The primary target audience includes patients with cancer and autoimmune diseases, as well as healthcare providers specializing in immunology and oncology.
Features
- CRISPR-based epigenetic modification for targeted immune suppression
- Cellular mechanism modulation to enhance immunotherapy response
- Enhanced efficacy of cancer immunotherapies
- Improved effectiveness of autoimmune disease treatments